Atlas Trials

A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

Clinical trial NCT05493267 · RECRUITING

Trial details

NCT number
NCT05493267
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
MDR-TBImmunotherapy
Start date
2022-08-03
Primary completion
2025-08-03
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.